Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2010

View Archived Issues

Novel DNA-alkylating agents described by Syntarga

Novel PI3K inhibitors presented by Shionogi

Kowa describes novel JAK inhibitors

Merck & Co. claims new antihypertensive agents

Cardiolynx patents new nitrate esters of valsartan and cilostazol

Long-term pimavanserin safe and well tolerated in Parkinson's disease psychosis

Pramipexole ER shows long-term efficacy and safety in advanced Parkinson's disease

GIND and ISB join to identify genes and targets involved in Huntington's disease

Milatuzumab-doxorubicin conjugate enters phase I/II trial in MM

Catena demonstrates visual benefits in Leber's hereditary optic neuropathy

TX-RAD completes preclinical development for inflammatory arthritis

Final phase II data on voreloxin/cytarabine in AML support phase III testing

SRX-251 shows favorable safety, tolerability and pharmacokinetics in healthy subjects

AZD-6244 is beneficial in phase II trial in IRPTC and PTC

CEP cells show promise as biomarker for response to antiangiogenic therapy in CRPC

Abbott and Neurocrine join to develop elagolix for endometriosis

Safety monitoring board recommends continuation of phase III Allovectin-7 trial

Durect reports on phase IIb hysterectomy trial of Posidur

Akebia's HIF-PH inhibitor AKB-6548 effective in phase Ib trial

Phase IIa trial of NU-1618 in hyperuricemia meets primary endpoint

Phase II trial of GDC-0449 in colorectal cancer does not meet primary endpoint

EMD Serono resumes BLP-25 liposome vaccine program in lung cancer

OBI-1 obtains positive opinion for orphan drug status in Europe

OncoMed and Bayer Schering form anticancer stem cell alliance

Thallion closes phase II TLN-232 trial following arbitral tribunal decision

Relypsa begins phase II trial of RLY-5016 for hyperkalemia

FDA approves Jevtana for metastatic hormone-refractory prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...